Literature DB >> 19050414

Treatment of ataxia and imbalance with varenicline (chantix): report of 2 patients with spinocerebellar ataxia (types 3 and 14).

Theresa A Zesiewicz1, Kelly L Sullivan.   

Abstract

Two patients with spinocerebellar ataxia (types 3 and 14) experienced marked improvement in their cerebellar symptoms shortly after taking varenicline (Chantix).

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 19050414     DOI： 10.1097/WNF.0b013e31818736a9

Source DB:  PubMed          Journal:  Clin Neuropharmacol        ISSN： 0362-5664            Impact factor:   1.592


  15 in total

1.  Analysis of gait in rats with olivocerebellar lesions and ability of the nicotinic acetylcholine receptor agonist varenicline to attenuate impairments.

Authors:  C S Lambert; R M Philpot; M E Engberg; B E Johns; L Wecker
Journal:  Behav Brain Res       Date:  2015-06-03       Impact factor: 3.332

Review 2.  Potential Therapeutic Application for Nicotinic Receptor Drugs in Movement Disorders.

Authors:  Maryka Quik; James T Boyd; Tanuja Bordia; Xiomara Perez
Journal:  Nicotine Tob Res       Date:  2019-02-18       Impact factor: 4.244

3.  Thalamic cholinergic innervation and postural sensory integration function in Parkinson's disease.

Authors:  Martijn L T M Müller; Roger L Albin; Vikas Kotagal; Robert A Koeppe; Peter J H Scott; Kirk A Frey; Nicolaas I Bohnen
Journal:  Brain       Date:  2013-09-20       Impact factor: 13.501

Review 4.  Exploring the Potential of Small Molecule-Based Therapeutic Approaches for Targeting Trinucleotide Repeat Disorders.

Authors:  Arun Kumar Verma; Eshan Khan; Sonali R Bhagwat; Amit Kumar
Journal:  Mol Neurobiol       Date:  2019-08-09       Impact factor: 5.590

5.  Therapeutic interventions in the primary hereditary ataxias.

Authors:  Gonzalo J Revuelta; George R Wilmot
Journal:  Curr Treat Options Neurol       Date:  2010-07       Impact factor: 3.598

6.  Methylphenidate for gait impairment in Parkinson disease: a randomized clinical trial.

Authors:  A J Espay; A K Dwivedi; M Payne; L Gaines; J E Vaughan; B N Maddux; J T Slevin; M Gartner; A Sahay; F J Revilla; A P Duker; R Shukla
Journal:  Neurology       Date:  2011-04-05       Impact factor: 9.910

7.  Neuronal nicotinic receptor agonists improve gait and balance in olivocerebellar ataxia.

Authors:  L Wecker; M E Engberg; R M Philpot; C S Lambert; C W Kang; J C Antilla; P C Bickford; C E Hudson; T A Zesiewicz; Peter P Rowell
Journal:  Neuropharmacology       Date:  2013-05-24       Impact factor: 5.250

Review 8.  Fragile X-associated tremor/ataxia syndrome: clinical phenotype, diagnosis, and treatment.

Authors:  Maureen A Leehey
Journal:  J Investig Med       Date:  2009-12       Impact factor: 2.895

9.  History of falls in Parkinson disease is associated with reduced cholinergic activity.

Authors:  N I Bohnen; M L T M Müller; R A Koeppe; S A Studenski; M A Kilbourn; K A Frey; R L Albin
Journal:  Neurology       Date:  2009-11-17       Impact factor: 9.910

Review 10.  Neurochemical Evidence of Preclinical and Clinical Reports on Target-Based Therapy in Alcohol Used Disorder.

Authors:  Santosh Kumar Prajapati; Shubham Bhaseen; Sairam Krishnamurthy; Alakh N Sahu
Journal:  Neurochem Res       Date:  2020-01-02       Impact factor: 3.996
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.